Opinion|Videos|January 24, 2025
Key Strategies for Preventing CRS and ICANS
Panelists discuss key strategies for preventing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients receiving bispecific therapies for B-cell lymphomas.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are your key strategies for preventing CRS and ICANS in patients receiving bispecific therapies for B-cell lymphomas?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care
2
Semaglutide Shows Promise for Steatohepatitis Resolution in MASH
3
Advancing Biomarker Testing Across GU, Lung, and Myeloma Care
4
Socioeconomic Factors Linked to Surgical Outcomes in Upper Extremity Soft Tissue Sarcoma
5
